FORM OF LOCK-UP AGREEMENTLock-Up Agreement • December 10th, 2010 • Glaxosmithkline PLC • Pharmaceutical preparations • New York
Contract Type FiledDecember 10th, 2010 Company Industry JurisdictionThe undersigned understands that you, as Representatives of the several Underwriters, propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the “Underwriters”), of Common Stock of the Company (the “Securities”) pursuant to a Registration Statement on Form S-1 to be filed with the Securities and Exchange Commission (the “Registration Statement”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.
WAIVER OF RIGHTS AND NOTICEWaiver of Rights And • December 10th, 2010 • Glaxosmithkline PLC • Pharmaceutical preparations
Contract Type FiledDecember 10th, 2010 Company IndustryThe undersigned stockholder of Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is a party to that certain Amended and Restated Investors’ Rights Agreement, dated December 24, 2008, as amended on July 22, 2010 (the “Rights Agreement”). Pursuant to Section 1.3 of the Rights Agreement, the undersigned has the right to be notified of a proposed underwritten public offering of the Company’s Common Stock and, under certain circumstances, to include in such public offering certain Registrable Securities (as defined in Section 1.1 of the Rights Agreement).
Anacor Pharmaceuticals, Inc. a Delaware corporation SERIES E PREFERRED STOCK PURCHASE AGREEMENT December __, 2008Preferred Stock Purchase Agreement • December 10th, 2010 • Glaxosmithkline PLC • Pharmaceutical preparations • California
Contract Type FiledDecember 10th, 2010 Company Industry JurisdictionThis Series E Preferred Stock Purchase Agreement (this “Agreement”) is made as of December , 2008, by and among Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A attached hereto (each, a “Purchaser” and, collectively, the “Purchasers”).